Tanabe Pharma’s dersimelagon hits success in Phase III EPP and XLP trial
EPP and XLR are rare diseases in which patients suffer with painful skin upon exposure to sunlight.
21 January 2026
21 January 2026
EPP and XLR are rare diseases in which patients suffer with painful skin upon exposure to sunlight.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.